[ad_1]
“Mass vaccination in Russia will begin in the coming months,” said Kremlin spokesman Dmitry Peskov. However, this is elegant wording that is mentioned in the German publication Handelsblatt. After the good news of the appearance of Sputnik V in the summer, immunization was due to begin in October. High-ranking Russian politicians were quick to announce this and the “world’s first coronavirus vaccine.”
Later, there was talk of November or December: “by the end of the year there will be between 3 and 8 million. vaccines’. Now Alexander Gincburg, director of the N. Gamaleius Institute for Research in Epidemiology and Microbiology, has set the vaccination date for January or February of next year. According to him, already at the beginning of next year there will be 5-6 million. dose of vaccine.
Two problems: premature and production capacity
Gincburg’s optimism may be overshadowed by a number of key issues: Moscow simply missed the essential third phase of the investigation by registering the vaccine in the summer, only to become a world leader in the fight against the coronavirus pandemic. Only now there are 40 thousand. studies in volunteers in Russia and Belarus, as well as clinical trials of the vaccine in the United Arab Emirates, India, Venezuela, Brazil and Egypt.
The Gamaleius Center recently announced that the efficiency of Sputnik V is 92 percent. This information was released a few days after vaccine developers at Pfizer and Biontech announced that their product is 90% effective. It is true that there are more and more reports of coronavirus infection in vaccine trials in Russia. It’s unclear whether they were vaccinated or given a placebo, and the Russians have yet to make the study results public.
The second problem is that Russia does not have the capacity to produce as many vaccines as planned. Pharmacists are also concerned about “vaccine stability,” which is the same quality for all vials, according to Handelsblatt.
Initially, the vaccine is produced in small quantities, around 500 ml in a bioreactor, and then the volume of the vaccine will have to be increased to tens of liters. However, this requires large capacity bioreactors and there are not many of them in Russia.
It is reported in the media that Putin has turned to French President F. Macron for help. On November 7 they called, and during the conversation, Putin asked if France could help Russia with mass production of the vaccine. The French president is said to have asked for time to think and consult with local scientists.
Russia expects a third of the market
Kirill Dmitryev, head of Russia’s direct investment fund, believes the country could occupy a third of the emerging billion-dollar vaccine against the coronavirus market. The same Russian possibility is offered by the American virologist Anthony Fauci, who pointed out that the vaccine developed by Biontech and Pfizer must be stored below -70 degrees. According to the expert, this could become a challenge for poor countries. The Russian vaccine can also be stored at room temperature.
However, Russian Sputnik may face another problem: In the West, Russian production is generally viewed critically. Researchers have already issued a warning not to register drugs that may later prove ineffective or even dangerous.
On the other hand, now is everyone’s time: the second wave of the coronavirus has hit both the West and Russia. The latter records new disease records daily. According to official data, more than 32 thousand people in the country died from coronavirus. people. In the regions of the country, as far as Moscow and St. Petersburg are concerned, doctors are already announcing the danger of crowded hospitals and a lack of inventory.
Not to mention, almost 95 percent. Moderna de America was also able to extract the effectiveness of the vaccine. Your vaccine doesn’t require a -70 degree cold like Pfizer. Therefore, Russia still has a long way to go to convince consumers that its vaccine is not only effective, but also somewhat better than that of other manufacturers. Not to mention the fact that countries like China or India have developed or are still developing their own vaccines.
The Covid-19 vaccine, developed by researchers from the German company BioNTech and the American corporation Pfizer, has shown extremely effective efficacy, the manufacturers say. According to them, it reduces the risk of developing coronavirus by up to 90%, but it will soon be known that not all countries will be able to take advantage of it.
See more about the vaccine in the TV3 report:
[ad_2]
